作者: Godwin, Kerry ; Saeed, Mohsan ; Amcheslavsky, Alla ; Wang, Yang ; Close, Brianna J ; Klempner, Mark S ; Coombes, Naomi ; Schneider, Ryan ; Hou, Shurong ; Ganesa, Chandrashekar ; Li, Qi ; Conway, Hasahn L ; Kurt Yilmaz, Nese ; Carroll, Miles W ; Schiffer, Celia A ; Chen, Da-Yuan ; Buttigieg, Karen R ; Ramchetty, Anudeep S ; Ejemel, Monir ; Schiller, Zachary A ; Wallace, Aaron ; Toomey, Jacqueline R ; Tree, Julia A ; Cavacini, Lisa A ; Elmore, Michael J

AbstractCOVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

作者: Hou, Shurong ; Wallace, Aaron L. ; Cavacini, Lisa A. ; Conway, Hasahn L. ; Ejemel, Monir ; Close, Brianna J. ; Mohsan, Saeed ; Klempner, Mark S. ; Yilmaz, Nese Kurt ; Schiffer, Celia A. ; Amcheslavsky, Alla ; Wang, Yang ; Li, Qi ; Schiller, Zachary A. ; Toomey, Jacqueline R. ; Schneider, Ryan ; Chen, Da-Yuan

SummaryCOVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

100 项与 MAb-362 (Masssachusetts Biologic Laboratories) 相关的药物交易

登录后查看更多信息